Related Experiment Video
Updated: Aug 14, 2026
09:53
Real-time In Vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase
Published on: April 23, 2019
Predictive testing of early CIN behaviour by molecular biomarkers
Summary
Molecular biomarkers like Ki-67 improve the prediction of cervical intraepithelial neoplasia (CIN) progression, reducing over-treatment. Combining biomarkers offers more accurate risk stratification for CIN management.
Area of Science:
- Gynecologic oncology
- Molecular pathology
- Biomarker research
Background:
- Cervical Intraepithelial Neoplasia (CIN) grading has low positive predictive value (PPV) for progression, leading to over-treatment.
- Current CIN grading systems show poor reproducibility and an average PPV of 16% for predicting progression to CIN-3.
Discussion:
- Molecular biomarkers, such as Ki-67, demonstrate higher PPV (30%) for predicting CIN progression compared to traditional grading.
- Quantitative Ki-67 models have been validated across multiple independent studies.
- Combining Ki-67 with retinoblastoma protein (Rb) and cytokeratins (CK-14/-13) further refines risk stratification for early CIN lesions.
Key Insights:
- Ki-67 alone improves CIN progression prediction by 14%, potentially impacting thousands of women annually in Europe.
- Combined Ki67-Rb analysis creates distinct risk groups: very low (0% progression) and high (48% progression).
- Further sub-classification using CK-14/-13 identifies intermediate (40% progression) and very high (100% progression) risk subgroups within high-risk patients.
Outlook:
- Widespread adoption of molecular biomarkers requires user-friendly equipment and adherence to Good Laboratory Practice (GLP) standards.
- Governmental support and industry collaboration are crucial for market penetration and validation.
- Continued PPV improvement is essential to minimize over-treatment in CIN management.
